"id:ID","studyTitle","studyRationale","uuid","studyVersion","studyAcronym","id"
"821","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","5036cf5b-7de7-4aa9-b257-4f4e9b8602db","2","H2Q-MC-LZZT","StudyVersion_1"
